News from ARVO 2011 annual meeting including Lucentis v Avastin in age-related macular degeneration

Pieter Droppert recently attended the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) in Fort Lauderdale.

Earlier in his career, Pieter worked in ophthalmology with Alcon Labs on European clinical trials for novel intra-ocular lenses.  He helped bring AcrySof® to market.

Hot news at this year’s ARVO was a discussion on the data published in the New England Journal of Medicine comparing FDA approved Lucentis® to off-label Avastin® in age-related macular degeneration (AMD).

If you are interested in the ophthalmology market or news from ARVO, Pieter has recently written a number of posts on Biotech Strategy Blog that are worth checking out:

, , , , , , , , , , , , , , ,

error: Content is protected !!